---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-238564"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-10-17T23:59:59+00:00"
generated_at: "2026-05-30T13:31:18.700683+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath reports preliminary Q3 revenue $11.2M; HEPZATO KIT sales trigger $25M warrant exercise

## Summary
- Preliminary Q3 2024 revenue of $11.2M, including $10M U.S. sales from HEPZATO KIT.
- Announcement of $10M U.S. quarterly revenue triggers exercise of Tranche B warrants from March 2023 PIPE.
- Warrant holders have 21 days to exercise at $6/share for aggregate $25M.
- Proceeds to support HEPZATO KIT commercial launch and fund new clinical trials for expanded indications.
- Final Q3 results and business update scheduled for investor call on November 8, 2024.

## SEC filing metadata
- accession: 0001193125-24-238564
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-10-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/0001193125-24-238564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/d837829d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-238564
- JSON: https://secwatch.observer/filing/0001193125-24-238564.json
- Plain text: https://secwatch.observer/filing/0001193125-24-238564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.